Aro Biotherapeutics, a clinical-stage biotechnology company working to develop potent and tissue-targeted medicines, today announced the dosing of the first patient in its clinical trial of ABX1100, a ...

Enterprise Products Partners is a top midstream company with potential for significant growth and strong returns. See why we ...

Thank you for standing by, and welcome to Enterprise Products Partners L.P.’s Fourth Quarter 2024 Earnings Conference Call.

The midstream energy giant reported solid fourth-quarter results, with notable advances in revenue and operational metrics.

In a report released today, Brandon Bingham from Scotiabank maintained a Hold rating on Enterprise Products Partners (EPD – Research Report), ...

The results topped Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment Research was for earnings of 69 cents per share. The provider of midstream energy ...

Enterprise Products Partners LP (EPD) released earnings for its fourth quarter that increased from the same period last year and ...

Enterprise Products Partners (EPD) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's ...

In the latest market close, Enterprise Products Partners (EPD) reached $33.45, with a -0.36% movement compared to the previous day. This move was narrower than the S&P 500's daily loss of 1.46%.

Citi analyst team at Citi has updated their financial outlook on Enterprise Products Partners (NYSE:EPD), increasing the price target to $37 from the previous $36, while reiterating a Buy rating on ...